Trial · NCT07477795
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 17 of 17
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Disease remission | At 6 months | Defined by National Institutes of Health (NIH) ≤ 1 at 6 months and with prednisone discontinuation |
| Secondary | Cumulative incidence of relapse | 12 months after treatment initiation | |
| Secondary | Cumulative incidence of treatment failure | 12 months after treatment initiation | |
| Secondary | Cumulative prednisone dose | 12, months after treatment initiation | |
| Secondary | Glucocorticoid-free disease remission | At 3 months | |
| Secondary | Glucocorticoid-free disease remission | At 6 months | |
| Secondary | Glucocorticoid-free disease remission | At 12 months | |
| Secondary | Cumulative incidence of Adverse Events and Serious Adverse Events | At 12 months | |
| Secondary | Change in the Physical Component Summary (PCS) of the SF36 | At 6 months | The Short Form (36) Health Survey is a 36-item measure if health status. The score obtained varies between 0 and 100. The higher the score the less disability. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992;30:473-83. |
| Secondary | Change in the Physical Component Summary (PCS) of the SF36 | At 12 months | The Short Form (36) Health Survey is a 36-item measure if health status. The score obtained varies between 0 and 100. The higher the score the less disability. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992;30:473-83. |
| Secondary | Change in vascular lesions | At 3 months | measured by angio CT and/or magnetic resonance imaging angiography and/or Doppler |
| Secondary | Change in vascular lesions | At 6 months | measured by angio CT and/or magnetic resonance imaging angiography and/or Doppler |
| Secondary | Change in vascular lesions | At 12 months | measured by angio CT and/or magnetic resonance imaging angiography and/or Doppler |
| Secondary | Change in vascular hypermetabolism | At 6 months | measured by 18-FDG-PET |
| Secondary | Change in vascular hypermetabolism | At 12 months | measured by 18-FDG-PET |
| Secondary | Cumulative incidence of revascularization procedures (endovascular or surgical) required because of disease | At 6 months | |
| Secondary | Cumulative incidence of revascularization procedures (endovascular or surgical) required because of disease | At 12 months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07477795/registered